Publication | Open Access

Sustained Response to Entrectinib in an Infant With a Germline ALKAL2 Variant and Refractory Metastatic Neuroblastoma With Chromosomal 2p Gain and Anaplastic Lymphoma Kinase and Tropomyosin Receptor Kinase Activation

Tumoral PathologyGermline Alkal2 VariantMedicinePharmacologyPathologyOncologyMalignant DiseaseAnaplastic Lymphoma KinaseRefractory Metastatic Neuroblastoma